PTC Therapeutics, Inc. Operating Lease, Liability, Noncurrent
PTC Therapeutics, Inc. (PTCT) had Operating Lease, Liability, Noncurrent of $87.53 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-07-30
- 2026-06-30: Operating Lease, Liability, Noncurrent $87.53M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $90.07M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $93.58M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $95.49M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $87.53M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $90.07M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $93.58M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $95.49M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $71.24M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $73.56M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $74.95M 10-K · filed 2026-02-19 |
| 2024-09-30 | $82.77M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $79.12M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $104.84M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $97.63M 10-K · filed 2025-02-27 |
| 2023-09-30 | $99.68M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $100.42M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $100.44M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $100.86M 10-K · filed 2024-02-29 |
| 2022-09-30 | $102.12M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $137.35M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $72.43M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $73.62M 10-K · filed 2023-02-21 |
| 2021-09-30 | $74.82M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $76.42M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $77.86M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $79.50M 10-K · filed 2022-02-22 |
| 2020-09-30 | $81.67M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $25.51M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $14.64M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $9.02M 10-K · filed 2021-02-25 |
| 2019-09-30 | $9.46M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $8.42M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $8.77M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |